PhD in Bioconjugation Chemistry: Developing Rearrangement Tools to Modify Natural Proteins

PhD in Bioconjugation Chemistry: Developing Rearrangement Tools to Modify Natural Proteins

Executive Verdict

P22 asks how new rearrangement chemistry can extend selective protein bioconjugation into dual-functional molecular tools. The core Conjugate Addition/Ring Expansion (CARE) approach already has a peer-reviewed 2026 demonstration on native protein N-termini; the proposed pathogenic-bacteria applications remain a further research goal. This distinction matters for applicants choosing between a reaction-development doctorate and a project with an established cellular endpoint.

The P22 project page describes a York-hosted, four-year project with Will Unsworth, Chris Spicer and Martin Fascione at York, Chris Schofield at Oxford, and the INEOS Oxford Institute for Antimicrobial Research as industrial partner. The employer recruitment text also lists Alistair Farley at Oxford; his formal role in the final supervisory team needs confirmation because the project page lists four supervisors.

For a Chinese applicant, however, application eligibility and financial usability must be separated. York publicly describes the CDT as open to international students, but its funding page specifies tuition fees at the UK rate. UKRI guidance likewise says that UKRI contributes only the home-rate fee and that international students may have to contribute to the difference. Programme material says international candidates can receive awards within the UKRI allocation cap, while recommending a separate scholarship for the overseas-fee gap. Therefore, a Chinese national can apply, but the public evidence does not prove that a P22 offer would automatically cover all overseas tuition for four years.

The opportunity is strongest for someone with genuine mechanistic and practical synthetic-organic capability who wants to develop protein chemistry and microbiology skills. It is less attractive for an applicant who needs a low-risk biological endpoint or cannot obtain written confirmation of the international fee arrangement before accepting an offer.

School, Programme, and Location Signal

York Chemistry has a strong UK subject and research signal. Its official department overview reports 8th in the UK for Chemistry in the 2027 Complete University Guide and 4th in the 2026 Times and Sunday Times Good University Guide. More importantly for a research doctorate, York's REF 2021 results describe Chemistry as a UK top-ten department in the Times Higher Education analysis, with 62% of submitted activity rated world-leading and 36% internationally excellent. Rankings cannot predict supervision quality, but this combination supports the department's research-environment signal.

The Centre for Doctoral Training model adds meaningful structure. The official application page advertises up to sixteen four-year studentships across the programme and requires applicants to apply to the host institution of their preferred projects. These are programme-wide places, not sixteen places on P22. The collected recruitment text specifies an initial four-month cohort training period at both Oxford and York, followed by an industry-co-supervised substantive project; P22 is primarily based at York. Joint provision does not by itself establish a joint degree: the awarding institution, registration and progression requirements still need confirmation. This matters because the scientific plan spans organic synthesis, chemical biology, antibiotics and bacterial targeted degradation rather than a narrow single-technique thesis.

The location is also useful at an ecosystem level. York has identifiable strength in chemical and structural biology, while the Oxford collaboration connects the project to an antimicrobial institute led by one of the named supervisors. The advantage is not simply two university names; it is access to complementary reaction-development, protein-chemistry and antimicrobial perspectives. The corresponding cost is complexity: travel, distributed supervision and industrial obligations can consume time unless roles are clearly defined.

Supervisor and Lab Assessment

Supervisor Research Directions

Will Unsworth's official profile centres on functionalised complex molecules, macrocycle synthesis and cascade ring-expansion reactions. That is the clearest match to the project's reaction-invention core: designing probes that undergo amine addition followed by rearrangement to expose a second reactive group.

Chris Spicer's profile describes protein modification, biomaterial conjugation, dynamic chemistry and bio-functionalisation. His role plausibly covers translation from probe synthesis to biomolecular selectivity, function and assay design.

Martin Fascione's institutional profile documents chemical glycobiology, protein bioconjugation, bacterial infection and a toolkit including synthetic chemistry, peptide synthesis, enzymatic/chemical protein modification and molecular enzymology. This is relevant to both the protein-conjugation and pathogen-facing elements.

Chris Schofield's Oxford profile identifies antibiotic resistance, metallo-enzymes and novel screening as major interests and names him as head of the INEOS Oxford Institute for Antimicrobial Research. This gives the proposed bacterial application a credible translation network, although the public project page does not specify a named industrial co-supervisor, placement or guaranteed assay package.

Taken together, the team is complementary rather than redundant. The main unresolved question is operational: who will supervise daily experiments, how frequently the confirmed supervisory team will make joint decisions, and how resources are divided between York and Oxford.

Recent Important Publications

• N-terminal protein-macrocycles enabled by conjugate addition/ring expansion cascade reactions, Chemical Science (2026). This is the direct project foundation. The authors used readily prepared acryloyl imides for selective N-terminal modification, with irreversible ring expansion producing stable conjugates. They demonstrated nanobody-based cancer-tissue imaging and altered chemokine-receptor signalling. The limitation is equally important: these results do not yet demonstrate pathogenic-bacteria delivery or induced bacterial protein degradation.
• Synthesis of medium-ring lactams and macrocyclic peptide mimetics via conjugate addition/ring expansion cascade reactions, RSC Chemical Biology (2022). This paper established the broader CARE reaction platform and iterative growth of macrocyclic peptide mimetics. It supports synthetic feasibility and scaffold diversity, but the work is mainly small-molecule chemistry rather than cellular biology.
• Site-selective protein modification via peptide-directed proximity catalysis, ACS Omega (2025). Fascione and Spicer's collaboration showed that catalyst-functionalised peptide ligands can direct installation of fluorophores and affinity handles and that changing catalyst position can change the modification site. It is not CARE chemistry, but it demonstrates continuing capability in selective protein functionalisation.
• Peptide modification via a mild carbonylative Suzuki–Miyaura reaction gives late-stage access to diaryl-ketones, Chemical Science (2026). Spicer and collaborators introduced photoaffinity handles into unprotected peptides under mild aqueous, open-atmosphere conditions. This supports the group's broader late-stage biomolecule-diversification capability, although it uses palladium chemistry and peptide rather than native-protein substrates.

The publication record therefore supports both the central method and adjacent techniques. The strongest evidence is the 2026 CARE protein paper because it is co-authored by the three York supervisors and directly anticipates P22.

Lab, Resources, and Collaboration Environment

The York Structural Biology Laboratory facilities page lists cloning, bacterial and insect-cell protein expression, chromatography-based purification, light scattering, mass spectrometry, analytical ultracentrifugation, fluorescence and time-resolved spectroscopy, microcalorimetry, surface-plasmon resonance and protein NMR access. This makes the advertised transition from synthetic probes to protein-level validation credible at an institutional level.

What is not public is project-specific access. Applicants should distinguish “the university owns this equipment” from “P22 has budgeted, scheduled and technically supported access.” The same applies to pathogen work: no species, containment level, delivery assay, bacterial protease system or Oxford-placement plan is stated. Those details will materially affect both scientific feasibility and daily work.

Research Direction and Field Outlook

Field Momentum

Selective native-protein modification is an active chemical-biology problem because many useful proteins cannot conveniently be engineered with a unique tag. CARE is attractive because it exploits N-terminal amine reactivity and then uses irreversible ring expansion to stabilise the conjugate. P22 proposes a further step: probes that undergo a CARE-like event and then reveal another reactive group, enabling dual-functional constructs with macrocycles and diversification or tagging handles.

The proposed bacterial-PROTAC application is timely but early. A 2024 Nature Communications study of targeted protein degradation in mycobacteria showed that induced degradation of essential bacterial proteins can inhibit growth and potentiate existing antibiotics. It also described bacterial targeted degradation as nascent. Unlike human-cell PROTACs, bacterial approaches must match a different proteolytic system, cross or exploit bacterial envelopes, retain target binding and avoid losing activity through efflux or metabolism.

That creates a useful but demanding thesis structure. The rearrangement and protein-conjugation chemistry can produce publishable platform advances even if the final cellular endpoint proves difficult, provided the project has explicit staged milestones and fallback aims. Without such staging, the student could spend too long trying to bridge multiple high-risk barriers at once.

Research Scope and Feasibility Questions

The advertisement identifies a broad progression from rearrangement chemistry to protein conjugation and possible antimicrobial applications. It leaves the detailed experimental plan open and does not guarantee a final bacterial-degradation result. A useful supervisor discussion would distinguish:

• Which findings already support the CARE platform, and which proposed applications still lack project-specific evidence?
• How will the thesis balance reaction development, protein chemistry and exploratory biological work, with appropriate supervision and facilities?
• What milestones and publishable fallback aims will be agreed if the later biological objectives prove infeasible?

These are questions about scope and support, not a proposed experimental sequence. The particular biological systems and safety arrangements remain to be confirmed by the project team.

Career and Market Outlook

The skills portfolio is broader than the phrase “bacterial PROTAC.” Likely destinations include academic chemical biology, protein or peptide conjugation, medicinal chemistry, bioconjugate/biologic development, assay development, antimicrobial discovery and platform-technology R&D. The UK's official life-sciences skills assessment projects around 66,000 additional priority jobs between 2025 and 2035 and reports strong demand for higher-level qualifications. The National Careers Service chemist profile also notes that many employers value a postgraduate qualification and identifies research institutes, public laboratories and commercial industry as common destinations.

These sector figures do not guarantee a bacterial-degrader job. The most portable outputs would be a clear methods portfolio: synthetic route design, rigorous compound and protein characterisation, quantitative selectivity/stability assays, reproducible data analysis, and experience translating a chemical tool into a biological question.

Funding, Application, and Living Cost

The collected recruitment text gives a first application deadline of 13 November 2026 at 12 noon, without specifying a time zone. Applications may continue afterwards, but some projects can fill in the first round; later acceptance should not be assumed. The start date remains unconfirmed.

Submit the online Chemistry PhD application with a 1,000-word personal statement explaining interest and experience, explicit first, second and third project choices at its end, university transcripts and the contact details of two academic or professional referees. York applicants must also complete the CSHP CDT Equality, Diversity and Inclusion data form. Project enquiries are listed as william.unsworth@york.ac.uk, chris.spicer@york.ac.uk and martin.fascione@york.ac.uk; general CDT enquiries are cshp-cdt@chem.ox.ac.uk or chem-env-pgr@york.ac.uk. The admissions FAQ says panel interviews assess a presentation on prior research, discussion of a supplied paper, programme/project questions and a synthetic-chemistry problem-solving exercise. Candidates then meet potential supervisors, and project allocation is influenced by interview ranking and preference order.

For Chinese applicants, the funding conclusion must remain precise:

• York states that the CDT is open to international and home students.
• York's project funding page describes stipend, research costs and tuition fees at the UK rate.
• UKRI lists a minimum stipend of £21,805 from October 2026 and a home-rate fee contribution of £5,238 for 2026/27, while warning that an international student may have to contribute to fees.
• Programme funding material states that international awards can be made within the UKRI allocation limit, but recommends a separate scholarship for the overseas-fee difference.
• York's international research-fee page shows that overseas Chemistry tuition is materially above the UKRI home-fee contribution and may rise with inflation.

The conclusion is that a Chinese national is eligible to apply, but financial closure requires a written answer naming the payer of the fee difference in each of the four years. “Students worldwide,” “open to international students,” and “fully funded” are not sufficient by themselves when the detailed fee wording is home-rate only.

York has operated a joint China Scholarship Council scheme that covered tuition, a living grant, one return flight and visa fees for Chinese nationals. However, the publicly available 2026/27 call was a separate, competitive, nomination-based award and described a typical three-year duration. It is evidence of a possible external route, not evidence that a 2027/28 four-year P22 award is covered. A fourth-year plan would be essential if this route were proposed.

Living costs require a separate budget from the unresolved tuition-fee gap. York's postgraduate living-cost guide identifies accommodation as the largest cost and notes that postgraduate contracts are typically 51 weeks. Its 2026/27 accommodation payment page gives a minimum self-catered cost of £185.64 per week, approximately £9,467.64 for 51 weeks. Against the £21,805 UKRI minimum, that leaves about £12,337 before food, local travel, personal expenses and savings. This is a conditional subtraction using the recorded minimum stipend and lowest listed rent, not confirmation of the P22 stipend, access to that room, or affordable living for a particular household. It excludes any overseas-fee gap and does not establish disposable savings; 2027/28 rent and other costs may differ.

Immigration costs sit outside ordinary monthly spending unless the award explicitly covers them. The UK Student visa page lists a £558 application fee, while the health-surcharge page lists £776 per year for students, normally collected upfront according to visa length.

Applicant Fit and Preparation

Best suited for

• Applicants with strong synthetic-organic or medicinal-chemistry training, especially reaction mechanism, heterocycle or macrocycle synthesis, purification and full structural characterisation.
• Chemical-biology applicants who can demonstrate both biomolecule handling and credible small-molecule synthesis.
• Researchers comfortable moving between probe design, aqueous reaction optimisation, intact-protein analysis and bacterial assays.
• Applicants who tolerate a high-risk endpoint and value a platform-method thesis with industrially relevant biological applications.

The collected P22 requirements accept applicants who hold or expect a minimum UK 2:1 honours degree or international equivalent in a relevant subject, usually chemistry or chemical engineering; applicants from other potentially relevant disciplines can ask the team. Research enthusiasm, independent thinking and working, analytical ability, and strong spoken and written communication are essential. Relevant laboratory experience strengthens fit but is not an additional universal degree requirement. The York Chemistry PhD entry page also gives a 2:1 in chemistry or a related subject, with international equivalents accepted. The recruitment text links to English-language requirements without stating test scores; those scores remain to be checked for the applicant and course. The York entry page warns that funded studentships are highly competitive and normally require a stronger academic profile than the minimum.

May need caution if

• The applicant wants a primarily computational or purely microbiological doctorate.
• The applicant has no evidence of independent synthetic laboratory work and does not want a substantial synthesis component.
• The applicant requires the final bacterial-PROTAC outcome to be predictable; that part of the field is still early.
• The applicant cannot obtain a written overseas-fee plan before commitment.
• The applicant prefers a single-supervisor environment with minimal travel or cross-site coordination.

Skills and evidence to strengthen

Application evidence should show more than course grades. Strong preparation would include:

• one example of independently troubleshooting a synthetic route and interpreting failure;
• confident use of NMR, LC-MS/HRMS and chromatographic purification;
• understanding of chemoselectivity, kinetics, buffer effects and protein-conjugate stability;
• practical or conceptual experience with protein expression/purification, intact-protein MS, fluorescence assays or microbiology;
• a mechanism-led reading of the 2026 CARE paper, including controls for N-terminal selectivity versus lysine labelling;
• a realistic view of bacterial uptake, efflux and protease-system compatibility;
• ability to present prior research clearly and critique an unfamiliar paper under interview conditions.

Risks and Questions to Verify

High-priority questions

1. For a Chinese national offered P22 at York, what exact organisation pays the overseas tuition-fee difference in each of the four years?
2. Does P22 include one of the limited international-funded places, or must a separate scholarship be won before the offer is financially valid?
3. If a York-CSC route is suggested, is there a confirmed 2027/28 call, and how are the fourth year, full overseas fee and stipend covered?
4. Who is the primary day-to-day supervisor, and what is the expected meeting cadence across the York and Oxford team?
5. Who is the named INEOS Oxford Institute co-supervisor, and what placement, compound library, assay or facility access is guaranteed?
6. Which bacterial species, target protein, degradation machinery and biosafety level are planned?
7. What are the 12- and 24-month go/no-go milestones, and what publishable fallback aims remain if cellular delivery or degradation fails?
8. How will N-terminal selectivity, off-target labelling, conjugate stability and preserved protein function be quantified?

Medium-priority questions

1. What fraction of the doctorate is expected to be small-molecule synthesis, protein chemistry, microbiology and data analysis?
2. Which instruments and protein-production services have project-specific budgeted access rather than general departmental availability?
3. How much York–Oxford travel is expected, and is it paid outside the stipend?
4. Are visa, immigration health surcharge, relocation and conference costs covered?
5. What industrial confidentiality or publication-review rules apply?
6. The employer recruitment text lists Alistair Farley as a fifth supervisor, while the official project page lists four; what is his formal role in the final supervisory team?

Evidence and Sources

The 2024 mycobacterial targeted-degradation study is field context, not a P22 result. The cited papers support the chemistry and tool claims stated above, but do not establish that the proposed bacterial endpoint will be achieved. The summaries here are inherited from the existing reports; paper-by-paper reading depth and full bylines are not recorded, so this is not a full-text methods review. Rankings, 2026/27 fees and rents, UKRI rates, immigration charges and the 2026/27 CSC call are tied to their stated years and should be checked against the actual offer.

Official project, programme and funding

• Official P22 project description
• CSHP CDT application process
• CSHP admissions FAQs
• University of York CSHP funding page
• UKRI support for funded students
• York international postgraduate research fees
• York-CSC scholarship page

School, supervisors and facilities

• York Chemistry department overview
• York REF 2021 results
• Will Unsworth profile
• Chris Spicer profile
• Martin Fascione profile
• Chris Schofield profile
• York Structural Biology Laboratory facilities

Publications and field evidence

• CARE N-terminal protein macrocycles, 2026
• CARE medium-ring lactams and peptide mimetics, 2022
• Peptide-directed proximity catalysis, 2025
• Mild peptide carbonylative coupling, 2026
• Targeted protein degradation in mycobacteria, 2024

Cost and career context

• York postgraduate living costs
• York accommodation payments
• UK Student visa
• UK immigration health surcharge
• UK life-sciences skills assessment
• National Careers Service chemist profile